The role of multidrug resistance protein (MRP-1) as an active efflux transporter on blood–brain barrier (BBB) permeability

2017 ◽  
Vol 21 (2) ◽  
pp. 355-365 ◽  
Author(s):  
Karthik Lingineni ◽  
Vilas Belekar ◽  
Sujit R. Tangadpalliwar ◽  
Prabha Garg
2004 ◽  
Vol 64 (9) ◽  
pp. 3296-3301 ◽  
Author(s):  
Salvatore Cisternino ◽  
Claire Mercier ◽  
Fanchon Bourasset ◽  
Françoise Roux ◽  
Jean-Michel Scherrmann

2021 ◽  
Vol 28 ◽  
Author(s):  
Ioannis Angelis ◽  
Vassilios Moussis ◽  
Demokritos C. Tsoukatos ◽  
Vassilios Tsikaris

: The main role of platelets is to contribute to hemostasis. However, under pathophysiological conditions, platelet activation may lead to thrombotic events of cardiovascular diseases. Thus, anti-thrombotic treatment is important in patients with cardiovascular disease. This review focuses on a platelet receptor, a transmembrane protein, the Multidrug Resistance Protein 4, MRP4, which contributes to platelet activation by extruding endogenous molecules responsible for their activation and accumulation. The regulation of the intracellular concentration levels of these molecules by MRP4 turned to make the protein suspicious and, at the same time, an interesting regulatory factor of normal platelet function. Especially, the possible role of MRP4 in the excretion of xenobiotic and antiplatelet drugs such as aspirin is discussed, thus imparting platelet aspirin tolerance and correlating the protein with the ineffectiveness of aspirin antiplatelet therapy. Based on the above, this review finally underlines that the development of a highly selective and targeted strategy for platelet MRP4 inhibition will also lead to inhibition of platelet activation and accumulation.


Sign in / Sign up

Export Citation Format

Share Document